Calydon Announces Issuance of Three Patents for Technologies for Targeting and Destroying Tumors, Including Prostate Cancer.SUNNYVALE, Calif.--(BW HealthWire)--Oct. 13, 1998--Calydon, Inc. today announced the issuance of three patents related to its technology for engineering viruses to replicate in and kill prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. cells. U.S. Patent 5,648,478 claims a human prostate tissue-specific enhancer (PSE PSE 1. pale soft exudative pork. 2. portosystemic encephalopathy. ) gene, and methods that utilize the PSE gene for treating prostate disease. U.S. Patent 5,698,443 claims methods for constructing a virus that incorporates the PSE gene for use in targeting and treating prostate cancer cells. U.S. Patent 5,783,435 claims methods and compositions for screening therapeutic agents for the treatment of prostate cancer. Calydon Inc., a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , is engaged in the discovery and development of new viral therapeutics that target prostate and other cancers. The company is focused on the development of tissue-specific viruses that selectively infect and destroy cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . The company is conducting a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for its prostate cancer therapeutic, CN706, at The Johns Hopkins Brady Urological Institute and The Johns Hopkins Oncology Center. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion